Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q1 2023 · 10-Q
Revenue$1.49M$1.49Mno prior Q1 2022 on file Net Income$276.66K$276.66Kno prior Q1 2022 on file EPS Diluted$0.00$0.00no prior Q1 2022 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
Operating Cash Flow-$28,061— Margins · derivedGross margin38.1%
Operating margin23.0%
Net margin18.6%
ended Apr 30, 2022 · filed Jun 15, 2022 · 46 d after period end